Genocea Biosciences, Inc. (GNCA): Price and Financial Metrics


Genocea Biosciences, Inc. (GNCA): $0.01

0.00 (-18.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GNCA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GNCA Stock Price Chart Interactive Chart >

Price chart for GNCA

GNCA Price/Volume Stats

Current price $0.01 52-week high $2.04
Prev. close $0.01 52-week low $0.01
Day low $0.01 Volume 473,511
Day high $0.01 Avg. volume 3,205,157
50-day MA $0.01 Dividend yield N/A
200-day MA $0.49 Market Cap 693.06K

Genocea Biosciences, Inc. (GNCA) Company Bio


Genocea Biosciences is a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company was founded in 2006 and is based in Cambridge, Massachusetts.


GNCA Latest News Stream


Event/Time News Detail
Loading, please wait...

GNCA Latest Social Stream


Loading social stream, please wait...

View Full GNCA Social Stream

Latest GNCA News From Around the Web

Below are the latest news stories about Genocea Biosciences Inc that investors may wish to consider to help them evaluate GNCA as an investment opportunity.

Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 th at 10:40 A.M. ET.

GlobeNewswire | February 10, 2022

The Petri Dish: Janssen inks two local deals, Biogen licenses new drug

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings.

Yahoo | January 6, 2022

Genocea to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.

GlobeNewswire | January 5, 2022

Needham Thinks Genocea Biosciences’ Stock is Going to Recover

In a report released today, Gil Blum from Needham maintained a Buy rating on Genocea Biosciences (GNCA – Research Report), with a price target of $6.00. The company's shares closed last Tuesday at $1.13, close to its 52-week low of $0.92. According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -25.0% and a 16.4% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals. Genocea Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $7.25, a 470.9% upside from current levels.

Catie Powers on TipRanks | January 4, 2022

Genocea Biosciences Provides Corporate Update

Enters into Inhibigen™ R&D collaboration and option agreement with Janssen Reports progress on the GEN-011 TiTAN™ trial CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, has entered into an R&D collaboration and option agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to explore the immunogenicity of neoantigens and t

Yahoo | January 4, 2022

Read More 'GNCA' Stories Here

GNCA Price Returns

1-mo -4.76%
3-mo -33.33%
6-mo -99.22%
1-year -99.48%
3-year -99.64%
5-year -99.91%
YTD -99.14%
2021 -52.07%
2020 16.91%
2019 -9.84%
2018 -75.26%
2017 -71.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4586 seconds.